Literature DB >> 9400986

Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection.

A Hossain1, T Holt, J Ciacci-Zanella, C Jones.   

Abstract

Small DNA viruses (adenoviruses, simian virus 40, or human papillomaviruses) induce S-phase progression but prevent cell division to provide precursors for viral DNA replication. Herpes simplex viruses types 1 or 2 (HSV-1 or HSV-2) contain genes which encode DNA-metabolizing enzymes, for example, ribonucleotide reductase, thymidine kinase and dUTPase, suggesting that S-phase factors are not required for an efficient infection. However, several studies indicated that HSV induces some events that occur during cell-cycle progression. To determine if HSV-2 induces S-phase entry, we examined serum-arrested African green monkey kidney cells (CV-1) after infection. Two hours after infection steady-state levels of the S-phase-specific cyclin, cyclin A, increased. S-phase cyclin-dependent kinase activity (CDK2) was stimulated 10-fold 8 h after infection but decreased at 16 or 24 h after infection. Mitotic CDK activity (CDC2) was not activated after infection, in part due to decreases in CDC2 protein levels and inactivation of enzymatic activity resulting from tyrosine phosphorylation of CDC2. Furthermore, CDK4 activity was not dramatically affected by infection. These studies indicate that HSV-2 infection selectively activates CDK2 after infection but cell-cycle progression does not occur. We hypothesize that infection activates certain components of the cell cycle which enhance viral gene expression and DNA replication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400986     DOI: 10.1099/0022-1317-78-12-3341

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

Review 1.  Herpesvirus lytic replication and the cell cycle: arresting new developments.

Authors:  E K Flemington
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  The disappearance of cyclins A and B and the increase in activity of the G(2)/M-phase cellular kinase cdc2 in herpes simplex virus 1-infected cells require expression of the alpha22/U(S)1.5 and U(L)13 viral genes.

Authors:  S J Advani; R Brandimarti; R R Weichselbaum; B Roizman
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Cell cycle regulation during viral infection.

Authors:  Sumedha Bagga; Michael J Bouchard
Journal:  Methods Mol Biol       Date:  2014

4.  The bovine herpesvirus 1 immediate-early protein (bICP0) associates with histone deacetylase 1 to activate transcription.

Authors:  Y Zhang; C Jones
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Cell cycle analysis of Epstein-Barr virus-infected cells following treatment with lytic cycle-inducing agents.

Authors:  A Rodriguez; E J Jung; E K Flemington
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.

Authors:  David L Evers; Julie M Breitenbach; Katherine Z Borysko; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.

Authors:  L M Schang; J Phillips; P A Schaffer
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.

Authors:  L M Schang; A Rosenberg; P A Schaffer
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Binding of herpes simplex virus type-1 virions leads to the induction of intracellular signalling in the absence of virus entry.

Authors:  Iain J MacLeod; Tony Minson
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

Review 10.  Chronic viral infection and primary central nervous system malignancy.

Authors:  Robert Saddawi-Konefka; John R Crawford
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.